Trastuzumab

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:monoclonal_antibody
gptkbp:administeredBy intravenous infusion
gptkbp:approvalYear 1998
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode L01XC03
gptkbp:biosimilar yes
gptkbp:brand gptkb:Herceptin
gptkbp:CASNumber 180288-69-1
gptkbp:combinationTherapy gptkb:cyclophosphamide
gptkb:capecitabine
gptkb:pertuzumab
gptkb:5-fluorouracil
gptkb:carboplatin
gptkb:doxorubicin
gptkb:cisplatin
gptkb:vinorelbine
gemcitabine
docetaxel
paclitaxel
epirubicin
gptkbp:contraindication pregnancy
severe hypersensitivity
gptkbp:developedBy gptkb:Genentech
gptkbp:discoveredBy gptkb:UCLA_researchers
gptkbp:eliminationHalfLife 5-12 days
gptkbp:firstApprovedIndication metastatic breast cancer
https://www.w3.org/2000/01/rdf-schema#label Trastuzumab
gptkbp:KEGGID D08141
gptkbp:legalStatus prescription only
gptkbp:marketedAs gptkb:Genentech
gptkb:Roche
gptkbp:mechanismOfAction inhibits proliferation of HER2-overexpressing cells
gptkbp:MedlinePlusID a697014
gptkbp:molecularWeight 148,000 Da
gptkbp:origin humanized monoclonal antibody
gptkbp:patentExpired yes
gptkbp:pregnancyCategory D (US)
gptkbp:PubChem_CID 123631
DB00072
CHEMBL1201587
gptkbp:routeOfAdministration subcutaneous
intravenous
gptkbp:sideEffect pulmonary toxicity
cardiotoxicity
infusion reactions
gptkbp:target gptkb:HER2_receptor
gptkbp:UNII P188ANX8CK
gptkbp:usedFor gptkb:HER2-positive_breast_cancer
HER2-positive gastric cancer
gptkbp:WHOModelListOfEssentialMedicines yes
gptkbp:bfsParent gptkb:Biocon_Biologics
gptkbp:bfsLayer 7